Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Health-Related Quality of Life in MONARCH 3: Abemaciclib Plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast CancerOncologist 2020 Jun 14;[EPub Ahead of Print], MP Goetz, M Martin, E Tokunaga, IH Park, J Huober, M Toi, C Stoffregen, S Shekarriz, V Andre, MC Gainford, GL Price, S Johnston
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.